Scarica l'app Stockscreener
103.22
0.29%
0.30
Dopo l'orario di chiusura:
103.22
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MIRM Giù?
Forum
Previsione
Precedente Chiudi:
$102.92
Aprire:
$102.85
Volume 24 ore:
805.34K
Relative Volume:
1.10
Capitalizzazione di mercato:
$6.18B
Reddito:
$379.25M
Utile/perdita netta:
$-77.34M
Rapporto P/E:
-64.02
EPS:
-1.6122
Flusso di cassa netto:
$-27.87M
1 W Prestazione:
+9.47%
1M Prestazione:
+30.91%
6M Prestazione:
+101.92%
1 anno Prestazione:
+113.09%
Intervallo 1D:
$100.62
$103.72
Intervallo di 1 settimana:
$93.23
$103.81
Portata 52W:
$36.88
$103.81
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Nome
Mirum Pharmaceuticals Inc
Settore
Industria
Telefono
650-667-4085
Indirizzo
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Confronta MIRM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
103.22 | 6.16B | 379.25M | -77.34M | -27.87M | -1.6122 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-24 | Iniziato | TD Cowen | Buy |
| 2025-08-11 | Ripresa | Stifel | Buy |
| 2025-05-19 | Ripresa | H.C. Wainwright | Buy |
| 2024-04-17 | Iniziato | Stifel | Buy |
| 2023-12-18 | Reiterato | H.C. Wainwright | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-11-13 | Iniziato | Morgan Stanley | Overweight |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-17 | Ripresa | Evercore ISI | Outperform |
| 2023-09-20 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2021-09-20 | Iniziato | JP Morgan | Overweight |
| 2020-08-07 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | Iniziato | H.C. Wainwright | Buy |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-06-25 | Iniziato | Robert W. Baird | Outperform |
| 2019-08-12 | Iniziato | Citigroup | Buy |
| 2019-08-12 | Iniziato | Evercore ISI | Outperform |
| 2019-08-12 | Iniziato | Guggenheim | Buy |
| 2019-08-12 | Iniziato | ROTH Capital | Buy |
| 2019-08-12 | Iniziato | Raymond James | Outperform |
Mostra tutto
Mirum Pharmaceuticals Inc Borsa (MIRM) Ultime notizie
Is Mirum Pharmaceuticals on a Strong Path to Profitability? - Finviz
Is Mirum Pharmaceuticals on a Strong Path to Profitability? - The Motley Fool
EV Market: Is Mirum Pharmaceuticals Inc impacted by rising rates2025 Winners & Losers & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Aug PreEarnings: Is Tronox Holdings plc impacted by rising ratesIndex Update & Trade Opportunity Analysis - baoquankhu1.vn
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $123.00 at Morgan Stanley - MarketBeat
Chronic hepatitis D market set for steady growth as pipeline inches forward - The Pharma Letter
H.C. Wainwright Raises PT on Mirum Pharmaceuticals For the Second Time In a Span of Two Weeks, Here is Why? - Finviz
11 Best Stocks to Buy for Investment - Insider Monkey
Subdued Growth No Barrier To Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) With Shares Advancing 25% - simplywall.st
HC Wainwright Has Negative Outlook of MIRM FY2027 Earnings - MarketBeat
Mirum Director Sells $400K Amid 91% Stock Surge -- Here's What the Firm Expects for 2026 - AOL.com
Heron Patrick J buys Mirum Pharmaceuticals shares worth $8.99m By Investing.com - Investing.com UK
Heron Patrick J buys Mirum Pharmaceuticals shares worth $8.99m - Investing.com
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells 1,053 Shares of Stock - MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) COO Sells $302,325.17 in Stock - MarketBeat
Jolanda Howe Sells 842 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock - MarketBeat
Christopher Peetz Sells 6,831 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock - MarketBeat
3 Stocks That May Be Trading Below Estimated Value By Up To 48.2% - simplywall.st
Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics - FinSMEs
Mirum acquires Bluejay Therapeutics to expand rare liver disease pipeline - Yahoo Finance
FY2030 Earnings Forecast for MIRM Issued By HC Wainwright - MarketBeat
Baird updates Mirum Pharmaceuticals (MIRM) valuation following beat-and-raise earnings results - MSN
Is Mirum Pharmaceuticals About to Soar in 2026? - Nasdaq
Mirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 12-Month High After Analyst Upgrade - MarketBeat
Aug Swings: What is the earnings history of Mirum Pharmaceuticals IncTrade Volume Report & Daily Technical Forecast Reports - baoquankhu1.vn
Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics; Closes Private Placements of $268.5 Million - marketscreener.com
Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease - Investing News Network
H.C. Wainwright raises Mirum Pharmaceuticals stock price target on volixibat potential - Investing.com Canada
Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Expert Outlook: Mirum Pharmaceuticals Through The Eyes Of 11 Analysts - Benzinga
Moving Averages: Does Mirum Pharmaceuticals Inc meet Warren Buffetts criteriaJuly 2025 Recap & AI Driven Stock Price Forecasts - baoquankhu1.vn
Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Eric Bjerkholt Sells 1,421 Shares - MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Sells $86,423.58 in Stock - MarketBeat
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) COO Sells 2,382 Shares of Stock - MarketBeat
Christopher Peetz Sells 7,098 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock - MarketBeat
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) Insider Sells $170,047.26 in Stock - MarketBeat
Mirum Pharmaceuticals CEO Sells Shares - TradingView
Mirum Pharmaceuticals stock hits all-time high at 95.75 USD By Investing.com - Investing.com Australia
Baird Updates Mirum Pharmaceuticals (MIRM) Valuation Following Beat-and-Raise Earnings Results - Finviz
Mirum Pharmaceuticals stock hits all-time high at 95.75 USD - Investing.com
Mirum Pharmaceuticals, Inc. $MIRM Shares Acquired by Emerald Advisers LLC - MarketBeat
14 Best Mid-Cap Growth Stocks to Buy Right Now - Insider Monkey
Mirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 52-Week HighHere's Why - MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) Insider Joanne Quan Sells 6,911 Shares - MarketBeat
CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy? - sharewise.com
Mirum stock rises 7% in a week: Here's what you should know - MSN
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Rating of "Buy" by Analysts - MarketBeat
23,566 Shares in Mirum Pharmaceuticals, Inc. $MIRM Bought by Campbell & CO Investment Adviser LLC - MarketBeat
Mirum Pharmaceuticals Inc Azioni (MIRM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):